Advancements in Stomach Cancer Treatment: Robotic Surgery, Targeted Chemotherapy, and Immunotherapy by Dr Tikfu Gee

-

Introduction

Explore the latest advancements in stomach cancer treatment, including the use of robotic surgery, targeted chemotherapy agents, and immunotherapy drugs. Discover how these treatments work and their potential to improve outcomes for patients.


Stomach cancer, or gastric cancer, is a formidable disease affecting countless individuals globally. Fortunately, medical science has made remarkable strides in stomach cancer treatment, leveraging innovative techniques like robotic surgery, targeted chemotherapy, and immunotherapy. This article delves into these cutting-edge advancements, shedding light on their mechanisms of action and potential benefits for patients.

Robotic surgery is a minimally invasive technique that has revolutionised the surgical treatment of stomach cancer. By employing robotic arms with precision instruments, surgeons can perform complex procedures with enhanced accuracy and reduced invasiveness. This approach involves smaller incisions, lowers the risk of complications, and facilitates a quicker recovery, ultimately improving post-surgery quality of life.

Chemotherapy remains a cornerstone of stomach cancer treatment, and recent developments in targeted therapies have shown promising results. Two notable agents used in targeted chemotherapy for stomach cancer are trastuzumab (Herceptin) and ramucirumab (Cyramza).

Trastuzumab is a targeted therapy that works by binding to the human epidermal growth factor receptor 2 (HER2) protein, which is over expressed in certain stomach cancers. By inhibiting HER2 signalling, trastuzumab halts the growth of cancer cells, thereby impeding tumour progression. This is particularly effective in cases where the tumour is HER2-positive, offering improved treatment outcomes.

Ramucirumab, on the other hand, is an angiogenesis inhibitor. It works by preventing the formation of new blood vessels that feed cancer cells, reducing their nutrient supply and limiting tumor growth. By targeting vascular endothelial growth factor receptor 2 (VEGFR2), ramucirumab inhibits angiogenesis, potentially improving overall survival rates.

Immunotherapy has emerged as a transformative approach in the treatment of various cancers, including stomach cancer. Pembrolizumab (Keytruda) and nivolumab (Opdivo) are two immunotherapy drugs that have exhibited promising results in advanced gastric cancer.

Pembrolizumab is a PD-1 checkpoint inhibitor that enhances the immune system's ability to recognize and destroy cancer cells. By blocking the PD-1 receptor on immune cells, pembrolizumab activates the immune response against the tumour, leading to tumour regression and improved survival rates in select patients with advanced gastric cancer.

Nivolumab, another PD-1 checkpoint inhibitor, has shown efficacy in treating patients with heavily pretreated advanced gastric cancer. By targeting the PD-1 pathway, nivolumab unleashes the immune system, enabling it to attack cancer cells that have evaded detection. This immunotherapeutic approach has demonstrated durable responses and improved overall survival rates for certain patients.

Conclusion

In conclusion, advancements in stomach cancer treatment, including robotic surgery, targeted chemotherapy agents like trastuzumab and ramucirumab, and immunotherapy drugs such as pembrolizumab and nivolumab, have opened new avenues for improving patient outcomes. These treatments target specific mechanisms, inhibiting tumour growth and harnessing the power of the immune system to combat cancer. As research progresses, we can anticipate further advancements in the fight against stomach cancer, offering hope for better treatments and outcomes for patients.


With hope and solidarity,

Dato Dr Tikfu Gee

#DrTikfuGee #DatoDrTikfuGee #DrGee #TikfuGee #StomachCancer # Treatment #RoboticSurgery #Chemotherapy #Immunotherapy


References:

  1. Deng J., You Q., Gao Y., Yu Q., Zhao P. & Zheng M. Recent advances in robotic surgery for gastric cancer (2021). J Laparoendosc Adv Surg Tech. DOI: 10.1089/lap.2021.0083 ↩

  2. Ajani J. A., Lee J., Sano T., Janjigian Y.Y., Fan D., Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 1;3:17036. DOI: 10.1038/nrdp.2017.36 ↩

  3. Cui J., Li X., Zhao J., Zhao P., Miao Y., Mao Z., Shen L. An updated meta-analysis of randomized controlled trials assessing the effect of TRastuzumab on operable HER2-Positive gastric cancer. Journal of Cancer. 2016;7(15):2343-2355. DOI: 10.7150/jca.15566 ↩

  4. Fuchs C.S., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-39. DOI: 10.1016/S0140-6736(13)61719-5 ↩

  5. Bang Y.J., Kang Y.K., Catenacci D.V.T., Muro K., Fuchs C.S., Geva R. Pembrolizumab in advanced gastric cancer. The New England Journal of Medicine. 2017;376:(22), 2040-2051. DOI: 10.1056/NEJMoa1612646 ↩

  6. Kang Y. K., Boku N., Satoh T., Ryu M.H., Chao Y., Kato K. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of at least two previous chemotherapy regimens. Lancet. 2017; 390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5 ↩

Comments

Post a Comment

Popular posts from this blog

The Role of H. Pylori in Stomach Cancer: What You Need to Know by Dr Tikfu Gee

-
Image
Introduction Helicobacter pylori (H. pylori) is a bacterium that infects the stomach lining and is known to be a significant risk factor for the development of stomach cancer. Understanding the relationship between H. pylori infection and stomach cancer is crucial in promoting prevention and early detection. In this blog post, we will explore the role of H. pylori in stomach cancer, highlighting the mechanisms, risk factors, and preventive measures, supported by relevant references. The Link Between H. Pylori Infection and Stomach Cancer 1. Mechanisms: H. pylori infection triggers chronic inflammation in the stomach lining, leading to genetic and epigenetic alterations in the cells. Prolonged inflammation and cellular changes increase the risk of malignant transformation and the development of stomach cancer. 2. Risk Factors:   Certain factors increase the likelihood of both H. pylori infection and stomach cancer. These include living in areas with a high prevalence of H. pylori in...
Read more

Stomach Cancer: Understanding the Symptoms and When to Get Screened by Dr Tikfu Gee

-
Image
Introduction Stomach cancer, also known as gastric cancer, is a type of cancer that develops in the lining of the stomach. It is a significant health concern worldwide, with varying incidence rates across different regions. Identifying and understanding the symptoms of stomach cancer play a crucial role in early diagnosis and effective treatment. In in blog post, we will explore the symptoms and signs of stomach cancer and discuss the recommended screening guidelines, supported by current research. Symptoms of Stomach Cancer 1. Abdominal Pain and Discomfort: Persistent abdominal pain and discomfort, particularly in the upper abdomen, may be indicative of stomach cancer. The pain can range from a dull ache to a burning sensation and may be intermittent or continuous. 2. Nausea and Vomiting:   Stomach cancer can cause persistent nausea and vomiting, which may worsen over time. These symptoms could be unrelated to meals and may be accompanied by a feeling of fullness or bloating. ...
Read more